Hypertension Clinical Trial
Official title:
Development and Implementation of an Innovative Technology for the Production New Generation Fruit and Vegetable Products Enriched With Dietary Fibre Preparation From Potato Starch With Prebiotic Properties for Children and Youth
The main goal of the project is to test fruit and vegetable mousse, with the addition of a fiber preparation made of potato starch with prebiotic properties, on selected clinical, metabolic and immunological parameters in overweight and obese children. The study will be performed in a group of 80 to 100 children aged 6 to 10 years (pre-pubertal age), using a double-blind procedure. Children will be randomly assigned into two groups, i.e. the intervention group (they will receive a vegetable and fruit mousse with the addition of potato starch fiber preparation with prebiotic properties) and the control group (they will receive an identical preparation in their diet, but without the addition of potato starch fiber preparation).
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 10 Years |
Eligibility | Inclusion Criteria: - overweight or obesity according to World Health Organization (WHO) definition - in 20 patients additionally to overweight or obesity also increase blood pressure - in 20 patients additionally to overweight or obesity also liver steatosis - willingness to participate Exclusion Criteria: - allergy to mousse components - malabsorption syndrome - organ failure - food neophobia - other diseases or health problems which may interfere with study procedures or safety. |
Country | Name | City | State |
---|---|---|---|
Poland | The Childen's Memorial Health Institute | Warszawa |
Lead Sponsor | Collaborator |
---|---|
Children's Memorial Health Institute, Poland | Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Poland, Jan Dlugosz University of Czestochowa, Poland, Oncology Center-Institute of Maria Sklodowska - Curie, Poland, Tymbark MWS Sp. with o.o. Sp. K., Poland |
Poland,
Barczynska R, Bandurska K, Slizewska K, Litwin M, Szalecki M, Libudzisz Z, Kapusniak J. Intestinal Microbiota, Obesity and Prebiotics. Pol J Microbiol. 2015;64(2):93-100. Review. — View Citation
Barczynska R, Kapusniak J, Litwin M, Slizewska K, Szalecki M. Dextrins from Maize Starch as Substances Activating the Growth of Bacteroidetes and Actinobacteria Simultaneously Inhibiting the Growth of Firmicutes, Responsible for the Occurrence of Obesity. — View Citation
Barczynska R, Slizewska K, Litwin M, Szalecki M, Kapusniak J. Effects of dietary fiber preparations made from maize starch on the growth and activity of selected bacteria from the Firmicutes, Bacteroidetes, and Actinobacteria phyla in fecal samples from o — View Citation
Litwin M, Michalkiewicz J, Trojanek J, Niemirska A, Wierzbicka A, Szalecki M. Altered genes profile of renin-angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension. 2013 Feb;61(2):431- — View Citation
Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R. Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens. 2007 Aug;20(8):875-82. — View Citation
Pinket AS, Van Lippevelde W, De Bourdeaudhuij I, Deforche B, Cardon G, Androutsos O, Koletzko B, Moreno LA, Socha P, Iotova V, Manios Y, De Craemer M; ToyBox-Study Group. Effect and Process Evaluation of a Cluster Randomized Control Trial on Water Intake — View Citation
Socha P, Grote V, Gruszfeld D, Janas R, Demmelmair H, Closa-Monasterolo R, Subías JE, Scaglioni S, Verduci E, Dain E, Langhendries JP, Perrin E, Koletzko B; European Childhood Obesity Trial Study Group. Milk protein intake, the metabolic-endocrine respons — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | BMI z-score change | Change in age and sex standardized BMI z-scores | 6 to 9 months | |
Secondary | Bioimpedance | Change in body composition on bioimpedance (fat-body-mass %) | 6 to 9 months | |
Secondary | Waist | Change in waist z-score (cm) | 6 to 9 months | |
Secondary | Gut microbiota | change in microbiome composition | 6 to 9 months | |
Secondary | Triglyceride | change in triglyceride-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | Cholesterol | change in cholesterol-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | Low-density lipoprotein (LDL) | change in Low-density lipoprotein (LDL)-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | high-density lipoprotein (HDL) | change in high-density lipoprotein (HDL)-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | very low-density lipoprotein (VLDL) | change in very low-density lipoprotein (VLDL)-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | apolipoprotein | change in apolipoprotein-parameter of lipid metabolism (mg%) | 6 to 9 months | |
Secondary | uric acid | change in uric acid (mg%) | 6 to 9 months | |
Secondary | leptin | change in leptin (ng/mL) | 6 to 9 months | |
Secondary | adiponectin | change in adiponectin (ng/mL) | 6 to 9 months | |
Secondary | glucose, serum | change in glucose (mg%) | 6 to 9 months | |
Secondary | insulin, serum | change in insulin (mcIU/mL) | 6 to 9 months | |
Secondary | Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) | change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), score, normal range<2,5 | 6 to 9 months | |
Secondary | Glutathione (GSH) | change in Glutathione (GSH) (g Hgb/mcL) | 6 to 9 months | |
Secondary | glutathione peroxidase (GPx) | change in glutathione peroxidase (GPx) (mg/dL) | 6 to 9 months | |
Secondary | total antioxidant status (TAS) | change in total antioxidant status (TAS) (mcmol/L) | 6 to 9 months | |
Secondary | tumor necrosis factor a (TNF-alfa) | change in tumor necrosis factor a (TNF-alfa) (ng/mL) | 6 months | |
Secondary | interleukin 6 (IL-6) | change in interleukin 6 (IL-6) (ng/mL) | 6 months | |
Secondary | Monocyte Chemoattractant Protein-1 (MCP-1) | change in Monocyte Chemoattractant Protein-1 (MCP-1) (ng/mL) | 6 months | |
Secondary | Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta | change in Macrophage Inflammatory Protein-1 (MIP-1) alfa and beta (ng/mL) | 6 months | |
Secondary | Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) | change in Regulated upon Activation, Normal T Cell Expressed and Presumably Secreted (RANTES) (ng/mL) | 6 months | |
Secondary | lymphocyte T | change in lymphocyte T (%) | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |